Lateral Flow Assays Market worth $13.52 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global lateral flow assays market will grow from USD 9.14 billion in 2026 to USD 13.52 billion by 2031, an 8.1% CAGR. North America held 42.3% of the market in 2025, while kits and reagents accounted for 82.3%; the report cites demand for rapid and home-based testing and advances in digital, multiplex, and higher-sensitivity assays as growth drivers. It also describes investment and deal activity, including OraSure’s USD 30 million investment in Sapphiros in January 2024 and Roche’s November 2025 supply and manufacturing option agreement with Sapphiros.

Analysis

The investable signal is not the market forecast; it is the possibility that scale and differentiated performance become more valuable than unit growth. High-volume manufacturing could lower test costs and strengthen Roche’s supply optionality, but also raises the bar for smaller producers: capacity alone does not establish demand, utilization, or attractive economics. If volume shifts toward smartphone-read, multiplex, or quantitative tests, value may accrue to validated assay IP, readers, and distribution—not uniformly to every company selling rapid tests.

Potential beneficiaries include Roche (ROP), with strategic access to Sapphiros capacity, and OraSure (OSUR), which has a stated investment and development relationship with Sapphiros. The financial pass-through to either is unknown; verify contract economics, ownership exposure, milestones, and actual orders before underwriting earnings. bioMérieux’s (BIM) SpinChip deal expands its point-of-care immunoassay capabilities, but should not be treated as proof of LFA revenue exposure. Broad portfolios at Abbott (ABT), Danaher (DHR), Becton Dickinson (BDX), and QuidelOrtho (QDEL) may offer resilience, yet the article provides no basis to rank their LFA contribution.

Near-term price impact should be limited: this is a vendor-sponsored forecast, not new audited company guidance. Over 1–3 months, watch disclosures for Sapphiros utilization, Roche order commitments, and OSUR’s economics. Over 6–18 months, clinical validation, regulatory clearance, reimbursement, and manufacturing yields determine whether higher-performance formats earn pricing power. Contrarian risk: market growth can coexist with weak returns if products commoditize or adoption lags. Thesis weakens if named partners report delays, low utilization, or no material revenue contribution.

Key Decisions for Investors

• No sector-wide trade on this release: treat the forecast as a demand hypothesis, not an earnings catalyst; avoid extrapolating market growth into listed-company revenue.
• Put ROP and OSUR on an event-driven watchlist rather than buying on the headline. Reassess only after verifying contract economics, Sapphiros production utilization, committed volumes, and OSUR’s attributable cash-flow or commercial rights.
• For BIM, track SpinChip regulatory and menu milestones separately from LFA adoption; do not assign LFA growth to the acquisition without evidence of product overlap or revenue contribution.
• Monitor company disclosures over the next 1–3 months and track utilization, order conversion, and product mix over 6–18 months. Delays, low utilization, or absent contribution to guidance would falsify the scale-and-premium thesis.